Hims vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Hims scores higher on our rubric, 7.9/10 against 7.5/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit Embody - our featured pick →or find your match

Hims beats Willow overall, scoring 7.9/10 vs 7.5/10. Published pricing is not a like-for-like monthly comparison: Hims is $188 first month, then $298/mo; Willow is from $299/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Willow for users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

A side-by-side look at Hims and Willow to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

Hims

#7 of 54

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy, Ozempic, Foundayo, and Zepbound paths and has since exited compounded semaglutide for new retail patients. The advertised medication floor is $149, but the required Weight Loss Membership adds $39 in month one and $149/month after that, so the all-in floor is $188 initially and $298 ongoing before any product- or dose-specific increase. Its parent still reports offering access to compounded GLP-1 medications on a limited scale (Q2 2026 results, filed with the SEC August 10, 2026). Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.

Visit Hims

Willow

#20 of 54

7.5/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only, Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	Hims	Willow
Why each one	The only publicly-traded men's telehealth (NYSE: HIMS) with FDA-approved Wegovy via direct Novo Nordisk partnership. Brand-name access plus SEC accountability, but balanced against a 3.0 Trustpilot rating that lags peers.	One of the few compounded-only platforms offering both injectable and daily oral semaglutide tablets, useful for users who want a non-injectable option without leaving the GLP-1 compounded category.
Our Score	7.9/10	7.5/10
Headline Price	$188 first month, then $298/mo	from $299/mo
Medication Type	Brand	Compounded
Insurance Accepted	No	No
Best For	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Watch out for	Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.	Compounded-only, no brand-name Wegovy or Zepbound through the platform
Ranking	#7	#20
Get started	Visit Hims	Visit Willow

Pros & Cons Compared

Hims

Pros

+Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+Medication starts at $149/mo for Wegovy pill, Foundayo, and Ozempic pill; Wegovy or Ozempic pens start at $199 and Zepbound at $299. The required membership makes the lowest all-in path $188 in month one and $298/mo ongoing, and exact product or dose can cost more.
+Polished app and web experience, among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.

Cons

−Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.
−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Do not confuse its $69 price with the current brand-name GLP-1 menu.
−The $149 GLP-1 figures are medication-only. A required Weight Loss Membership costs $39 in month one and $149/mo ongoing, so a $149 medication path totals at least $188 initially and $298/mo after that.
−Cash-pay only, Hims does not bill insurance, so an insured buyer may do better on a copay.
−Generic high-volume support, large patient base means less personalized attention than smaller competitors.

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide, one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only, no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses, starting dose is $399/mo
−Cash-pay only, no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024, less track record than Ro or Hims, though growth has been fast

Our Verdict

Hims edges out Willow with a score of 7.9/10 vs 7.5/10. Published pricing is not a like-for-like monthly comparison: Hims is $188 first month, then $298/mo; Willow is from $299/mo.